Skip to content

PolitiKit

Lobbying by Merck Canada Inc.: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.

← Lobbying

Corporation

Merck Canada Inc.

Meetings this Parliament
58
With MPs
11
Since Nov 2021
117
Active registrations
1

Most recent reported meeting: Sep 30, 2026.

Registrations in effect

In-house (corporation) In effect since Aug 25, 2026

Filed by David D. Jones, PRESIDENT

Lobbyists

  • David D. Jones · PRESIDENT
  • Jannie Oosthuizen · EVP, Oncology & MSD International
  • Jean-Philippe D’Aoust · Associate Director, Policy and Government Relations
  • Jennifer Chan · Vice President, Policy & Communications
  • Octavio Rego · Dir, Key Account Management, Policy & Ext Affairs - Quebec/Atlantic
  • Philippe Houle · Executive Director Policy & Government Affairs
  • Sandra Wainwright · Director - Regulatory Affairs
  • Sean Kinney · Associate Director - Patient Access

Institutions they may lobby: Agriculture and Agri-Food Canada (AAFC), Canadian Institutes of Health Research (CIHR), Canadian International Trade Tribunal (CITT), Competition Tribunal (CT), Crown-Indigenous Relations and Northern Affairs Canada (CIRNAC), Employment and Social Development Canada (ESDC), Environment and Climate Change Canada (ECCC), Finance Canada (FIN), Fisheries and Oceans Canada (DFO), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Justice Canada (JC), National Research Council (NRC), Natural Resources Canada (NRCan), Natural Sciences and Engineering Research Council (NSERC), Office of the Information Commissioner of Canada (OIC), Office of the Privacy Commissioner of Canada (OPC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Safety Canada (PS), Public Services and Procurement Canada (PSPC), Senate of Canada, Statistics Canada (StatCan), Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)

What they're lobbying on (33)
  • Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.
  • Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes.
  • Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussed
  • Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP).
  • World Health Organization issues concerning pharmaceuticals as it relates to Counterfeits, Access to Medicines, and the Intergovernment Working Group (IGWG).
  • US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.
  • The government's Science and Technology strategy as it relates to the biopharmaceutical industry.
  • Subsequent Entry Biologics (SEBs) as it relates to Regulations, Policies, or Guidelines being developed by Health Canada, specifically the Draft Guidance Document on SEBs, the Notices of Changes to Health Canada's Guidance Documents on Data Protection and Patented Medicines Regulations (Notice of Compliance) Regulations.
  • Smart Regulations as it relates to the biopharmaceutical industry.
  • Scientific Research and Educational Design (SR&ED) Tax Credit in respect of updating the system and increasing the expenditure limit for refundable credits.
  • Policies and programs as it relates to vaccine approval, procurement and public awareness of immunization.
  • Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services.
  • Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.
  • Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.
  • Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.
  • Patented Medicines (Notice of Compliance) Regulations as it relates to the regulation of intellectual property for biopharmaceutical products.
  • Patent Act as it relates to reporting requirements and pricing guidelines, and the protection of intellectual property in biopharmaceutical products.
  • Partnership opportunities as it relates to Canada's policy and programs to improve health in the developing world, such as Maternal and Child Health.
  • New Substances Notification Regulations as it relates to the biopharmaceutical industry.
  • National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.
  • Income Tax Act as it relates to biopharmaceutical products.
  • Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.
  • Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.
  • Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.
  • Federal Government involvement in national strategies to address major chronic diseases having a significant burden on the Canadian health care system, such as Dementia, Diabetes, Hepatitis C and Cancer and major public health concerns such as Antimicrobial resistant.
  • Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).
  • Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.
  • Canadian Institutes of Health Research (CIHR) Clinical Research Initiatives as it relates to public/private research and development partnerships and to the Drug Safety and Effective Network (DSEN).
  • Canadian Environmental Protection Act and Regulations in respect of modern, science-based regulations to reflect rapidly changing new technologies.
  • Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.
  • Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.
  • Anti-Counterfeit Trade Agreement (ACTA) as it concerns counterfeit drugs.
  • Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.

Registration 959141-12241-54. Look it up in the official Registry

Reported meetings

Spreadsheet

Filed by David D. Jones (63), Marwan Akar (54).

  • Reported by David D. Jones · In-house (corporation)

    • James Hwang · Constituency Assistant, House of Commons
    National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework. Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes.

    Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.

    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Sony Perron · Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    and 6 more
    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Policy Advisor, Health Canada (HC)
    • Linsey Hollett · Assistant Deputy Minister, Health Canada (HC)
    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting. Read more

    Policies and frameworks to accelerate access to innovative medicines post-Health Canada approval, including efforts to reduce time to reimbursement and streamline federal/provincial listing processes.

    Common Drug Review Policies as it relates to reimbursement recommendation decision-making process and framework.

    Policy measures to ensure security of drug supply in Canada and preserve Canada’s attractiveness for biopharmaceutical launches, including in response to foreign pricing regulations.

    Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
    Smart Regulations as it relates to the biopharmaceutical industry. Read more

    Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.

    National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.

    The government's Science and Technology strategy as it relates to the biopharmaceutical industry.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products. Read more

    Smart Regulations as it relates to the biopharmaceutical industry.

    National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.

    The government's Science and Technology strategy as it relates to the biopharmaceutical industry.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Caroline Menard · Manager, Innovation, Science and Economic Development Canada (ISED)
    The government's Science and Technology strategy as it relates to the biopharmaceutical industry.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Justine Frame · Policy Advisor, Health Canada (HC)
    Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products. Read more

    Smart Regulations as it relates to the biopharmaceutical industry.

    National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework.

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Chanel Sterie · Senior Advisor, Public Services and Procurement Canada (PSPC)
    • Kabisan Thanendran · Policy advisor, Public Services and Procurement Canada (PSPC)
    Plan design and reimbursement policies for drug plans administered by Federal Government including NIHB and Corrections Services.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Dominic LeBlanc · President of the King's Privy Council for Canada and Minister of International Trade and Intergovernmental Affairs
    • Karim Bardeesy · Member of Parliament
    • Marjorie Michel · Minister of Health, Health Canada (HC)
    • Janice Charette · Chief Trade Negotiator to the United States, Privy Council Office (PCO)
    and 7 more
    • Ritu Banerjee · Assistant Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Martin Moen · Associate Asst Dep. Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
    • Manuela Tomic · Senior Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    • Sandenga Yeba · Director of Policy & Deputy Chief of Staff, Health Canada (HC)
    • Justine Frame · Special Assistant- Policy, Health Canada (HC)
    • Shalene Curtis-Micallef · Deputy Minister, Health Canada (HC)
    National Pharmaceutical Strategy as it relates to the federal government's involvement in federal/provincial access to medicines framework. Read more

    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.

    Pharmaceutical pricing policy issues arising from the jurisdiction of the Patended Medicines Prices Review Board (PMPRB) and R&D reporting.

    Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH).

    US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.

    Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.

    Food and Drug Regulations as it relates to data protection and the regulation and protection of biopharmaceutical products.

    Patented Medicines Regulations as it relates to the regulation and protection of biopharmaceutical products.

    Annual federal Budgets and Budget updates as it relates to the biopharmaceutical industry, and related updates and to Federal budgetary policy.

    Food and Drugs Act and Regulations and the Import and Export Permits Act with respect to cross-border trade as it relates to the export of Canadian biopharmaceuticals.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Nasser Haidar · Senior Policy Advisor, Intergovernmental Affairs Secretariat (IGA)
    Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP). Read more

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • David K Lee · Chief Regulatory Officer, Health Canada (HC)
    Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPs) with respect to the protection of data, Access to Medicines, and TRIPs "flexibility". Merck is seeking to ensure Canada's continued compliance with its obligations under TRIPs relevant to the biopharmaceutical industry within all domestic legislation in addition to ongoing and future trade negotiations. Relevant domestic legislation includes the Food and Drugs Act, the Patent Act, and related regulations and guidance documents. Beyond TRIPs, Merck is seeking enhancements to increase the stability and global competitiveness of Canada’s intellectual Property legislation, regulations and policies relevant to the biopharmaceutical industry. Such enhancements may result from domestic policy in addition to bilateral and multilateral trade negotiations (e.g. Comprehensive Economic and Trade Agreement (CETA) and the Trans-Pacific Partnership (TPP). Read more

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Martin Moen · Associate Asst Dep. Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
    • Loris Mirella · Director - Intellectual Property Trade Policy, Global Affairs Canada (GAC)
    • Gabrielle Dolgoy · Acting Deputy Director, Global Affairs Canada (GAC)
    • David Norris · Senior Trade Policy Officer, Global Affairs Canada (GAC)
    Any and all free trade treaty agreements as it relates to the North American Free Trade Agreement (NAFTA) and trade negotiations between Canada as it relates to the European Union, India, Japan and the Trans-Pacific Partnership. International trade policies in support of the biopharmaceutical industry, including competitive and predictable intellectual property protection, product regulation and patient access to medicines. Read more

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Karim Bardeesy · Member of Parliament
    • Chase Knight · Parliamentary Secretary Assistant and Parliamentary Affairs Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Lisa Xie · Policy Advisor, Innovation, Science and Economic Development Canada (ISED)
    • Victoria Morton · Senior Communications Advisor, House of Commons
    The government's Science and Technology strategy as it relates to the biopharmaceutical industry. Read more

    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Annahat Kochhar · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Hosai Zurmati Halim · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Read more

    The government's Science and Technology strategy as it relates to the biopharmaceutical industry.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    • Justine Frame · Special Assistant- Policy, Health Canada (HC)
    The government's Science and Technology strategy as it relates to the biopharmaceutical industry. Read more

    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • ritu Banerjee · Assistant deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Greg Orencsak · Deputy Minister, Health Canada (HC)
    • Sarah Lawley · Assistant Deputy Minister, Health Canada (HC)
    • Pamela Aung-Thin · Assistant Deputy Minister, Health Canada (HC)
    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Read more

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Mark Schaan · Associate Deputy Minister, Innovation, Science and Economic Development Canada (ISED)
    • Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
    The government's Science and Technology strategy as it relates to the biopharmaceutical industry.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Jocelyne Voisin · Senior Assistant Deputy Minister, Health Canada (HC)
    • Daniel MacDonald · Director General, Health Canada (HC)
    Establish accountability with the federally financed Canadian Agency for Drugs and Technologies in Health (CADTH). Read more

    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Ian Foucher · Chief of Staff, Finance Canada (FIN)
    • Scott Winter · Director General, International Trade Policy Division, Finance Canada (FIN)
    • Matthew O'Connell · Deputy Director Financial Sector Policy, Finance Canada (FIN)
    US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    and 11 more
    • Brandan Rowe · Chief of Staff, Privy Council Office (PCO)
    • Rob Stewart · Deputy Minister of International Trade, Global Affairs Canada (GAC)
    • Martin Moen · Associate Asst Dep. Minister, Trade Policy and Negotiations, Global Affairs Canada (GAC)
    • Jason LaTorre · Director General, Global Affairs Canada (GAC)
    • Holly Duggan · Director of Outreach and Stakeholder Relations, House of Commons
    • David McFarlane · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
    • Eve Loignon-Giroux · Senior Communications Advisor, Privy Council Office (PCO)
    • Darren Hall · Director of Data Management, House of Commons
    • Wilder Walker-Stewart · Director Of Policy, Public Services and Procurement Canada (PSPC)
    • Yianni Papadatos · Director of Parliamentary Affairs, Public Services and Procurement Canada (PSPC)
    • Kabisan Thanendran · Policy advisor, Public Services and Procurement Canada (PSPC)
    US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Elliott Lockington · Chief of Staff, Treasury Board Of Canada Secretariat (TBS)
    • Elizabeth Wong · Policy Advisor, Treasury Board Of Canada Secretariat (TBS)
    US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    • Justine Frame · Special Assistant- Policy, Health Canada (HC)
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    • Bryn Savage · Policy Advisor, Health Canada (HC)
    US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Maggie Chi · Member of Parliament
    • Karina Gould · Leader of the Government in the House of Commons
    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    • Yash Nanda · Policy Advisor, Finance Canada (FIN)
    and 2 more
    • David McFarlane · Director of Policy, Innovation, Science and Economic Development Canada (ISED)
    • Jade Mallette · Chief of Staff, Health Canada (HC)
    Patented Medicines (Notice of Compliance) Regulations with respect to ensuring that patent rights are respected and are internationally competitive.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
    • Shahad Khalladi · Senior Policy Advisor, Health Canada (HC)
    • Justine Frame · Special Assistant- Policy, Health Canada (HC)
    US - Canada Regulatory Cooperation Council (RCC) as it relates to the regulation of biopharmaceutical products. Read more

    Health Canada's Legislative and Regulatory Modernization (LRM) as it relates to the review, approval, transparency and compliance activities of biopharmaceutical products. Health Canada's Regulatory Roadmap for Health Products and Food as it relates to proposed policy and regulatory changes related to the review, approval, transparency and compliance activities of biopharmacuetical products.

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • David K Lee · Chief Regulatory Officer, Health Canada (HC)
    Discussion focused on sharing perspectives on priorities and resourcing. In particular, a shared observation of an increase in submission reviews exceeding established timeframes and increasing challenges with securing pre-filing meetings were discussed Read more

    Official report

  • Reported by David D. Jones · In-house (corporation)

    • Mackenzy Metcalfe · Policy Advisor, Finance Canada (FIN)
    Canada's Access to Medicines Regime with respect to ensuring that the program allows for the delivery of timely access to needed medicines to the developing world supported by a business climate in Canada that continues to encourage research into further treatment and prevention of disease. Read more

    Official report

From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.